Literature DB >> 6124375

Metabolism of carbamazepine.

K Lertratanangkoon, M G Horning.   

Abstract

Thirty-two metabolites of carbamazepine, in addition to the 10,11-epoxide, have been isolated from enzymatically hydrolyzed urine by HPLC and identified by gas-chromatographic and mass-spectrometric techniques. Eight were sulfur-containing methylthio, methylsulfinyl, or methylsulfonyl derivatives. Eighteen new metabolites, including five iminostilbene derivatives that have not been described earlier, were found. All of the metabolites were formed by processes involving epoxidation and a peroxidation, the structures of the metabolites support the hypothesis that multiple epoxides and a cyclic peroxide are involved in the in vivo metabolism of carbamazepine by the rat and man.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124375

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  23 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Metabolic interaction between imipramine and carbamazepine in vivo and in vitro in rats.

Authors:  W Daniel; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

3.  Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites in vitro.

Authors:  R J Riley; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 4.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 5.  Genetic factors in the predisposition to drug-induced hypersensitivity reactions.

Authors:  Munir Pirmohamed
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

6.  The use of transgenic cell lines for evaluating toxic metabolites of carbamazepine.

Authors:  C R Valentine; J L Valentine; J Seng; J Leakey; D Casciano
Journal:  Cell Biol Toxicol       Date:  1996-06       Impact factor: 6.691

Review 7.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

8.  Pharmacokinetic interaction between carbamazepine and neuroleptics after combined prolonged treatment in rats.

Authors:  W Daniel; L Janczar; L Danek; W Legrum; K J Netter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-05       Impact factor: 3.000

9.  Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry.

Authors:  Jinsong Ni; Hui Ouyang; Mauro Aiello; Carmai Seto; Lisa Borbridge; Takeo Sakuma; Robert Ellis; Devin Welty; Andrew Acheampong
Journal:  Pharm Res       Date:  2008-02-26       Impact factor: 4.200

10.  Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.

Authors:  M Pirmohamed; A Graham; P Roberts; D Smith; D Chadwick; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.